ArticleChemistry (Weinheim an der Bergstrasse, Germany)2016
d- Versus l-Glucose Conjugation: Mitochondrial Targeting of a Light-Activated Dual-Mode-of-Action Ruthenium-Based Anticancer Prodrug.
Article in Chemistry (Weinheim an der Bergstrasse, Germany), 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed.
- Recent Advances in the Development of Metal-Glycoconjugates for Medicinal Applications.Molecules (Basel, Switzerland) · 2025Review
- Recent Advances in Photodynamic Therapy: Metal-Based Nanoparticles as Tools to Improve Cancer Therapy.Pharmaceutics · 2024Review
- Ruthenium-Based Photoactivated Chemotherapy.Journal of the American Chemical Society · 2023Review
- Adding Diversity to a Diruthenium Biscyclopentadienyl Scaffold via Alkyne Incorporation: Synthesis and Biological Studies.Inorganic chemistry · 2023Article
- Encapsulation of Ru(II) Polypyridine Complexes for Tumor-Targeted Anticancer Therapy.BME frontiers · 2023Review
- Ru(II) CONTAINING PHOTOSENSITIZERS FOR PHOTODYNAMIC THERAPY: A CRITIQUE ON REPORTING AND AN ATTEMPT TO COMPARE EFFICACY.Coordination chemistry reviews · 2022Article
- Metalloimmunotherapy with Rhodium and Ruthenium Complexes: Targeting Tumor-Associated Macrophages.Chemistry (Weinheim an der Bergstrasse, Germany) · 2022Article
- Stimuli-responsive platinum and ruthenium complexes for lung cancer therapy.Frontiers in pharmacology · 2022Review
- Photoactivable Ruthenium-Based Coordination Polymer Nanoparticles for Light-Induced Chemotherapy.Nanomaterials (Basel, Switzerland) · 2021Article
- Targeting drug delivery with light: A highly focused approach.Advanced drug delivery reviews · 2021Review
- Critical discussion of the applications of metal complexes for 2-photon photodynamic therapy.Journal of biological inorganic chemistry : JBIC : a publication of the Society of Biological Inorganic Chemistry · 2020Review
- Dual-Action Ru(II) Complexes with Bulky π-Expansive Ligands: Phototoxicity without DNA Intercalation.Inorganic chemistry · 2020Article
- ATP7B Binds Ruthenium(II)Inorganic chemistry · 2019Article
- Photochemical Resolution of a Thermally Inert Cyclometalated Ru(phbpy)(N-N)(Sulfoxide)Journal of the American Chemical Society · 2019Article
- Synthesis of O-1- O-6 Substituted Positional Isomers of d-Glucose-Thioether Ligands and Their Ruthenium Polypyridyl Conjugates.The Journal of organic chemistry · 2018Article
- Catch and Release Photosensitizers: Combining Dual-Action Ruthenium Complexes with Protease Inactivation for Targeting Invasive Cancers.Journal of the American Chemical Society · 2018Article
- New Ru(ii) complex for dual photochemotherapy: release of cathepsin K inhibitor andDalton transactions (Cambridge, England : 2003) · 2018Article
- Effects of the Bidentate Ligand on the Photophysical Properties, Cellular Uptake, and (Photo)cytotoxicity of Glycoconjugates Based on the [Ru(tpy)(NN)(L)]Chemistry (Weinheim an der Bergstrasse, Germany) · 2018Article
- The development of anticancer ruthenium(ii) complexes: from single molecule compounds to nanomaterials.Chemical Society reviews · 2017Review
- d- Versus l-Glucose Conjugation: Mitochondrial Targeting of a Light-Activated Dual-Mode-of-Action Ruthenium-Based Anticancer Prodrug.Chemistry (Weinheim an der Bergstrasse, Germany) · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Light-activated ruthenium polypyridyl anticancer prodrugs often suffer from poor water solubility, poor selectivity, and/or ill-defined intracellular targets. Coordination of the d- or l-glucose thioether ligand 3 (2-(2-(2-(methylthio)ethoxy)ethoxy)ethyl-β-glucopyranoside) to the highly lipophilic ruthenium complex [Ru(tpy)(dppn)(H
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.